Does Disease Burden on PET Predict Outcomes for Advanced NSCLC Patients Treated With First-Line Immunotherapy?

T Y Andraos,B Halmos,H Cheng, C Huntzinger,S Shirvani,N Ohri

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS（2021）

引用 0|浏览1

暂无评分

摘要

For advanced NSCLC patients treated with first-line IT, having OMD is a favorable prognostic factor. Volume of disease on FDG-PET could provide additional prognostic information. The presence of brain metastases does not seem to affect outcomes, which may reflect the activity of IT in the central nervous system and should be considered when designing clinical trials.

查看译文

关键词

pet predicts outcomes,advanced nsclc patients,immunotherapy,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要